Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales

Abstract

Background: Experience in real clinical practice with ceftazidime-avibactam for the treatment of serious infections due to gram−negative bacteria (GNB) other than carbapenem-resistant Enterobacterales (CRE) is very limited. Methods: We carried out a retrospective multicenter study of patients hospitalized in 13 Italian hospitals who received ≥72 h of ceftazidime-avibactam for GNB other than CRE to assess the rates of clinical success, resistance development, and occurrence of adverse events. Results: Ceftazidime-avibactam was used to treat 41 patients with GNB infections other than CRE. Median age was 62 years and 68% of them were male. The main causative agents were P. aeruginosa (33/41; 80.5%) and extended spectrum beta lactamase (ESBL)-producing Enterobacterales (4/41, 9.8%). Four patients had polymicrobial infections. All strains were susceptible to ceftazidime-avibactam. The most common primary infection was nosocomial pneumonia (n = 20; 48.8%), primary bacteremia (n = 7; 17.1%), intra-abdominal infection (n = 4; 9.8%), and bone infection (n = 4; 9.8%). Ceftazidime-avibactam was mainly administered as a combination treatment (n = 33; 80.5%) and the median length of therapy was 13 days. Clinical success at the end of the follow-up period was 90.5%, and the only risk factor for treatment failure at multivariate analysis was receiving continuous renal replacement therapy during ceftazidime-avibactam. There was no association between clinical failures and type of primary infection, microbiological isolates, and monotherapy with ceftazidime-avibactam. Only one patient experienced recurrent infection 5 days after the end of treatment. Development of resistance to ceftazidime-avibactam was not detected in any case during the whole follow-up period. No adverse events related to ceftazidime-avibactam were observed in the study population. Conclusions: Ceftazidime-avibactam may be a valuable therapeutic option for serious infections due to GNB other than CRE.

No Decrease in Infection Rate with the Use of Local Vancomycin Powder After Partial Hip Replacement in Elderly Patients with Comorbidities

“…All of these organisms are defined as multidrug-resistant gram-negative bacteria and well-known pathogens responsible for nosocomial infections. These infections are most probably resistant to vancomycin and occur particularly in patients in ICUs [ 13 , 14 ]. The reason for the predominance of these bacteria might be due to the fact that five of the six patients in our study who developed post-operative SSI had follow-ups in the ICU in the early post-operative period.…”

Molecular Mechanisms, Epidemiology, and Clinical Importance of β-Lactam Resistance in Enterobacteriaceae

“…A multicenter retrospective study performed in Italy between 2016 and 2019 revealed a high clinical success rate in patients who received ceftolozane-tazobactam in empiric and/or targeted therapy for severe infections [ 176 ]. Concerning new drugs for a carbapenem-sparing approach, a recent real-life study assessed the role of ceftazidime-avibactam for the targeted treatment of patients with ESBL-E infections in selected cases, but the small study sample limited the drawing of definitive conclusions [ 177 ].…”

Costo-efectividad de ceftazidima/avibactam versus colistin + meropenem en el tratamiento de infecciones por enterobacterias resistentes a carbapenémicos en Chile

“…Ceftazidima/avibactam, con registro sanitario en Chile desde julio de 2019 14 , y aprobación por el Instituto de Salud Pública de las cuatro indicaciones de la EMA, es una combinación novel donde avibactam tiene actividad contra las enzimas β-lactamasas de la clase A y la clase C según Ambler, incluidas las enzimas β-lactamasas de espectro extendido (BLEEs), las carbapenemasas KPC y las enzimas AmpC; y también sobre la carbapenemasa OXA-48 de la clase D 15 .…”